US5733781AExpiredUtility

Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus

59
Assignee: GEN PROBE INCPriority: Jul 19, 1994Filed: Jul 19, 1994Granted: Mar 31, 1998
Est. expiryJul 19, 2014(expired)· nominal 20-yr term from priority
Inventors:Thomas B. RyderTheodore Jesse Kwoh
C12N 15/1132A61P 31/12C12N 2310/315A61P 31/18A61K 38/00
59
PatentIndex Score
23
Cited by
49
References
104
Claims

Abstract

The present invention concerns the use of oligonucleotides to inhibit propagation of human immunodeficiency virus (HIV). Preferred HIV target sites are identified and oligonucleotides designed to hybridize to a target site, or be analogous to a target site, are described. The preferred use of the oligonucleotides is to inhibit HIV propagation in a patient infected with HIV.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. An oligonucleotide consisting of a nucleic acid sequence selected from the group consisting of: SEQ. ID. NOS: 1-18 and 20-25, wherein said oligonucleotide optionally contains one or more modified sugars and optionally contains one or more modified internucleoside linkages, and wherein said oligonucleotide inhibits HIV propagation. 
     
     
       2. The oligonucleotide of claim 1, wherein said oligonucleotide is optionally modified with one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate; and said oligonucleotide is optionally modified with one or more 2'-O-methyloligonucleotides. 
     
     
       3. The oligonucleotide of claim 1, wherein said oligonucleotide is a DNA oligonucleotide optionally containing one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate. 
     
     
       4. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 1. 
     
     
       5. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 2. 
     
     
       6. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 3. 
     
     
       7. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 4. 
     
     
       8. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 5. 
     
     
       9. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 6. 
     
     
       10. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 7. 
     
     
       11. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 8. 
     
     
       12. The oligonucleotide of claim 1, wherein said nucleic acid sequence is SEQ ID NO 9. 
     
     
       13. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 10. 
     
     
       14. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 11. 
     
     
       15. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 12. 
     
     
       16. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 13. 
     
     
       17. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 14. 
     
     
       18. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 15. 
     
     
       19. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 16. 
     
     
       20. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 17. 
     
     
       21. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 18. 
     
     
       22. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 20. 
     
     
       23. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 21. 
     
     
       24. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 22. 
     
     
       25. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 23. 
     
     
       26. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 24. 
     
     
       27. The oligonucleotide of claim 3, wherein said nucleic acid sequence is SEQ ID NO 25. 
     
     
       28. The oligonucleotide of any of claims 1 or 3-27, wherein at least 50% of the internucleoside linkages of said oligonucleotide are phosphorothioate linkages. 
     
     
       29. The oligonucleotide of claim 28, wherein all of the internucleoside linkages of said oligonucleotide are phosphorothioate linkages. 
     
     
       30. An oligonucleotide consisting of a sequence which may differ by a 0 to 10% base difference, excluding RNA and DNA equivalents, and which may have up to 4 additional nucleotides or up to two outside nucleotides deleted, from a nucleic acid sequence selected from the group consisting of: SEQ. ID. NOS: 3-10, 12-18, and 20-25, wherein said oligonucleotide optionally contains one or more modified sugars and optionally contains one or more modified internucleoside linkages, and wherein said oligonucleotide inhibits HIV propagation. 
     
     
       31. The oligonucleotide of claim 30, wherein said oligonucleotide is a DNA oligonucleotide optionally containing one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate. 
     
     
       32. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 3. 
     
     
       33. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 4. 
     
     
       34. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 5. 
     
     
       35. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 6. 
     
     
       36. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 7. 
     
     
       37. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 8. 
     
     
       38. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 9. 
     
     
       39. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 10. 
     
     
       40. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 12. 
     
     
       41. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 13. 
     
     
       42. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 14. 
     
     
       43. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 15. 
     
     
       44. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 16. 
     
     
       45. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 17. 
     
     
       46. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 18. 
     
     
       47. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 20. 
     
     
       48. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 21. 
     
     
       49. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 22. 
     
     
       50. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 23. 
     
     
       51. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 24. 
     
     
       52. The oligonucleotide of claim 31, wherein said nucleic acid sequence is SEQ ID NO 25. 
     
     
       53. A method of inhibiting propagation of HIV comprising the step of incubating an HIV infected cell in culture with an oligonucleotide under conditions where said oligonucleotide inhibits HIV propagation, wherein said oligonucleotide consists of a nucleic acid sequence selected from the group consisting of SEQ. ID. NOS: 1-18 and 20-25, and wherein said oligonucleotide optionally contains one or more modified sugars and optionally contains one or more modified internucleoside linkages. 
     
     
       54. The method of claim 53, wherein said oligonucleotide is optionally modified with one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate; and said oligonucleotide is optionally modified with one or more 2'-O-methyloligonucleotides. 
     
     
       55. The method of claim 53, wherein said oligonucleotide is a DNA oligonucleotide optionally containing one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate. 
     
     
       56. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 1. 
     
     
       57. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 2. 
     
     
       58. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 3. 
     
     
       59. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 4. 
     
     
       60. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 5. 
     
     
       61. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 6. 
     
     
       62. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 7. 
     
     
       63. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 8. 
     
     
       64. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 9. 
     
     
       65. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 10. 
     
     
       66. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 11. 
     
     
       67. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 12. 
     
     
       68. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 13. 
     
     
       69. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 14. 
     
     
       70. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 15. 
     
     
       71. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 16. 
     
     
       72. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 17. 
     
     
       73. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 18. 
     
     
       74. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 20. 
     
     
       75. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 21. 
     
     
       76. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 22. 
     
     
       77. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 23. 
     
     
       78. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 24. 
     
     
       79. The method of claim 55, wherein said nucleic acid sequence is SEQ ID NO 25. 
     
     
       80. The method of any of claims 53 or 55-79, wherein at least 50% of the internucleoside linkages of said oligonucleotide are phosphorothioate. 
     
     
       81. The method of claim 80, wherein all of the internucleoside linkages of said oligonucleotide are phosphorothioate linkages. 
     
     
       82. A method of inhibiting propagation of HIV comprising the step of incubating an HIV infected cell in culture with an oligonucleotide under conditions where said oligonucleotide inhibits HIV propagation, wherein said oligonucleotide is 18 to 100 nucleotides in length and comprises a sequence having no more than a 10% nucleotide base difference, excluding RNA and DNA equivalents, from a nucleic acid sequence selected from the group consisting of: SEQ. ID. NOS: 3-10, 12-18, and 20-25, and wherein said oligonucleotide optionally contains one or more modified sugars and optionally contains one or more modified internucleoside linkages. 
     
     
       83. The method of claim 82, wherein said oligonucleotide is a DNA oligonucleotide optionally containing one or more modified internucleoside linkages each independently selected from the group consisting of: phosphorothioate, methylphosphonate and phosphorodithioate. 
     
     
       84. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 3. 
     
     
       85. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 4. 
     
     
       86. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 5. 
     
     
       87. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 6. 
     
     
       88. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 7. 
     
     
       89. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 8. 
     
     
       90. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 9. 
     
     
       91. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 10. 
     
     
       92. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 12. 
     
     
       93. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 13. 
     
     
       94. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 14. 
     
     
       95. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 15. 
     
     
       96. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 16. 
     
     
       97. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 17. 
     
     
       98. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 18. 
     
     
       99. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 20. 
     
     
       100. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 21. 
     
     
       101. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 22. 
     
     
       102. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 23. 
     
     
       103. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 24. 
     
     
       104. The method of claim 83, wherein said nucleic acid sequence is SEQ ID NO 25.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.